SANTA MONICA, Calif. — GoodRx (Nasdaq: GDRX) announced it is expanding access to Eli Lilly and Company’s newly approved oral GLP-1 medication, Foundayo (orforglipron), along with the Zepbound (tirzepatide) KwikPen, offering discounted self-pay pricing through its nationwide pharmacy network.
Eligible patients can access Foundayo starting at $149 per month through GoodRx, while Zepbound KwikPen will be available starting at $299 per month at more than 70,000 pharmacies across the United States. The company said the initiative aims to improve access to weight management treatments, particularly for patients without insurance coverage for these medications.
The rollout reflects growing demand for GLP-1 therapies, including newer oral options, as well as a shift toward alternative access models outside traditional insurance pathways.
“We’re excited to work with Lilly to help bring one of the most anticipated innovations in weight management to patients,” said Wendy Barnes, president and CEO of GoodRx. “As new GLP-1 therapies continue to expand, including oral options like Foundayo, it is critical that access evolves alongside innovation. By pairing transparent cash pricing with nationwide pharmacy access and integrated care, we are helping ensure more people understand their options and more easily start treatment.”
GoodRx said the program provides transparent pricing and allows patients to fill prescriptions at their preferred local pharmacies, helping reduce barriers to starting and maintaining treatment.
“The launch of Foundayo reflects Lilly’s continued commitment to expanding treatment options for people living with obesity and advancing meaningful innovation in this category,” said Laura Steele, group vice president of U.S. cardiometabolic health at Eli Lilly and Company. “We’re committed to expanding access to treatment options through channels that meet patients where they are in their journey.”
The company said its platform supports pharmaceutical manufacturers in offering consumer-direct pricing at scale, combining discounted cash pricing with nationwide pharmacy access. This approach is becoming increasingly important as insurance coverage for certain high-cost therapies, including GLP-1 drugs for weight loss, remains inconsistent.
GoodRx said the expanded offerings are intended to help patients better understand their treatment options and improve access to prescribed obesity care while maintaining continuity with their existing healthcare providers.
